Immune System Diseases

905 trials 381 recruiting

Filter these 905 trials by phase, country and sponsor.

Open in Search →

Phase 2 Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) Ended

2023-504825-38-00 Lupus Nephritis (LN) Immunoglobulin A Nephropathy (IgAN 4 2022-04-15
A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patient… Ended

2024-514130-20-00 complement 3 glomerulopathy (C3G)/immune complex membr 5 2022-04-04
A study to evaluate efficacy, safety and tolerability, pharmacokinetics and pharmacodynamics of emapalumab in children and adults with macro… Ended

2024-516153-52-00 Macrophage activation syndrome (MAS) in the context of 10 2022-03-28
A Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety and Radiological and Clinical Effects of Subcutaneous (SC) Ocrelizumab… Ended

2023-505975-54-00 Multiple Sclerosis (MS) 5 2022-03-28
U3P study - Upadacitinib in Psoriatic Arthritis Pain Processing Ended

2024-512669-15-00 Psoriatic arthritis 6 2022-03-24
Isatuximab in type I cryoglobulinemia: A prospective pilot study ICE STUDY Ended

2024-515039-31-00 Isatuximab in type I cryoglobulinaemia: A prospective p 4 2022-02-10
An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasth… Ended

2024-510932-36-00 Generalized Myasthenia Gravis (gMG) 5 2021-12-21
An Open-Label, Randomized, Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Pegcetacoplan in the Treatment of Post-Transplan… Ended

2024-511544-36-00 complement 3 glomerulopathy (C3G)/immune complex membra 4 2021-12-21
Obinutuzumab for primary membranous nephropathy: a pilot study in patients with rituximab-resistant or rituximab-dependent nephrotic syndrom… Ended

2024-515857-93-00 Primary Membranous Nephropathy 4 2021-12-17
Study for the research of predictive factors of response to Tofacitinib therapy in patients with ulcerative rectal colitis. Ended

2024-518577-34-00 Ulcerative colitis 6 2021-12-16
A Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis Ended

2023-509782-20-00 Diffuse Cutaneous Systemic Sclerosis 4 2021-11-11
Rescue Therapy with the Human Anti-CD38 Antibody MOR202 (felzartamab) in Patients with Membranous Nephropathy who Failed Anti-CD20 Target Th… Ended

2024-513744-28-00 Membranous nephropathy 4 2021-10-22
RepurpSS-II study Ended

2024-510904-36-00 primary Sjögren's Syndrome 4 2021-10-12
Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Gia… Ended

2024-510744-31-00 Giant cell arteritis (GCA) 5 2021-10-06
A study to learn how safe bimekizumab, how well it works and how it moves through the bloodstream in adolescents with moderate to severe pla… Ended

2023-509832-24-00 Moderate to Severe Plaque Psoriasis 4 2021-08-30
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disea… Ended

2023-504156-10-00 Plaque Psoriasis. 5 2021-08-13
A single patient trial with Ataluren in one case of severe common variable immunodeficiency with autoimmunity due to homozygous stop codon m… Ended

2024-518919-19-00 LRBA deficiency due homozygous nonsense mutations. It i 4 2021-07-09
An extension study to learn if Bimekizumab is safe and works as a long-term therapy in adults with moderate to severe hidradenitis suppurati… Ended

2024-511035-10-00 Hidradenitis Suppurativa 5 2021-06-23
Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN) Ended

2023-507977-16-00 Lupus Nephritis (LN) Immunoglobulin A Nephropathy (IgAN 4 2021-05-10
A Multicentre, Open-Label, Single Ascending Dose, Dose-Ranging, Phase I/IIa Study to Evaluate the Safety and Tolerability of an Autologous A… Ended

2024-512579-11-00 Prophylaxis against renal transplant rejection 7 2021-03-17
Clinical Study of the Efficacy, Safety and Pharmacokinetics of Ustekinumab as Intravenous Induction Treatment Followed by Subcutaneous Ustek… Ended

2023-504978-38-00 Moderately to Severely Active Crohn's Disease 5 2021-03-16
A Clinical Study of the Efficacy, Safety and Pharmacokinetics of Ustekinumab as Intravenous Induction Treatment Followed by Subcutaneous Ust… Ended

2023-504977-19-00 Moderately to Severely Active Ulcerative Colitis 5 2021-03-15
Epitope open-label extension study to evaluate the long-term clinical benefit and safety of DBV712 in peanut-allergic children (EPOPEX) Ended

2024-515703-19-00 Peanut allergy 5 2021-03-02
Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosis Ended

2024-513075-40-00 Relapsed or refractory AL amyloidosis 4 2021-03-01